AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
AbbVie agreed to pay up to $2.54 billion to Disco Pharmaceuticals for rights to develop AND-gated bispecific therapeutics for solid tumors. The deal marks an expansion into next-generation cancer medi
reuters · 2026-11-18 23:06 UTC